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Abstract: B-Raf is one of the more commonly mutated proto-oncogenes implicated in the 
development of cancers.  In this review, we consider the mechanisms and clinical impacts of 
B-Raf mutations in cancer and discuss the implications for the patient in melanoma, thyroid 
cancer and colorectal cancer, where B-Raf mutations are particularly common. 
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Introduction 
B-RAF is known as v-raf murine sarcoma viral homolog B1 which is a proto-
oncogene.  It is a member of Raf (Rapidly accelerated fibroblast) kinase family proteins.  Raf 
kinase family proteins are serine/threonine kinases, originally identified as retroviral 
oncogenes in 1983 (Moelling et al., 1984; Rapp et al., 1983; Zebisch and Troppmair, 2006).  
So far, the Raf kinase proteins have had three members identified and they are: A-Raf, B-Raf 
and C-Raf.  C-Raf, also known as Raf-1, was first discovered in 1985 whereas A-Raf was 
discovered in 1986 and B-Raf in 1988 (Bonner et al., 1985; Huebner et al., 1986; Ikawa et al., 
1988; Roskoski, 2010).  A-Raf is the smallest isoform, at 68 kDa, C-Raf ranges from 72-74 
kDa and due to some significant alternative splicing, B-Raf ranges from 75 to 100 kDa 
(Barnier et al., 1995; Storm et al., 1990; Wellbrock and Karasarides, 2004).  
All Raf proteins share a common structure of three conserved region: CR1, CR2 and 
CR3 (Fig. 1).  CR1 and CR2 are regulatory domains which exist in the N-terminus whereas 
CR3 is a kinase domain which is encoded in the C-terminus (Morrison and Cutler, 1997; 
Wellbrock and Karasarides, 2004).  CR1 contains the Ras binding domain (RBD) and 
cysteine rich domain (CRD).  It is responsible for binding with Ras and membrane 
phospholipids (Roskoski, 2010).  Although Ras binds to RBD only in its active form (Ras-
GTP), binding to CRD does not depend on GTP status of Ras (Wellbrock and Karasarides, 
2004; Wittinghofer and Nassar, 1996).  CR2 is a serine/threonine rich region. Protein-protein 
interactions and phosphorylation through CR2 interfere with Raf activation and localization 
(Guan et al., 2000; Morrison et al., 1993; Yao et al., 1995; Zhang and Guan, 2000; 
Zimmermann and Moelling, 1999).  In addition, CR2 holds a phosphorylation site which is 
responsible for binding to the regulatory protein 14-3-3. Besides the site in the CR2, there is 
another binding site for the 14-3-3 regulatory protein after the CR3 region.  The CR3 region 
Page 3 of 35 
 
itself is a catalytic kinase domain which is regulated through phosphorylation (Roskoski, 
2010). 
B-Raf is the most potent activator of downstream effector MEK kinases in the Ras-
Raf-MEK-ERK pathway when compared with A-Raf and C-Raf (Cantwell-Dorris et al., 
2011; Moelling et al., 1984; Rapp et al., 1983).  The reason for this is that residue S446 in B-
raf is constitutively phosphorylated and becomes negatively charged.  In addition, residue 
D449 in B-Raf contains aspartic acid (instead of tyrosine) which is a negatively charged 
amino acid.  Both of the residues are in N-region of B-Raf.  As a result, B-Raf always has a 
negatively charged N-region, which facilitates its activation through Ras (Cantwell-Dorris et 
al., 2011; Garnett and Marais, 2004; Mason et al., 1999).   On the other hand, C-Raf and A-
Raf require their N-region (residues S338 and Y341 in C-Raf, residues S229 and Y302 in A-
Raf) to be phosphorylated by Src in addition with phosphorylation by Ras for their full 
activation (Fabian et al., 1993; Garnett and Marais, 2004; Marais et al., 1995; Mason et al., 
1999).  B-Raf also possesses the highest basal kinase activity among all Raf isoforms.  All 
these factors give B-Raf predominance over other Raf isoforms for MEK activation 
(Cantwell-Dorris et al., 2011).  
The maintenance of homeostasis in the Ras-Raf-MEK-ERK pathway requires strict 
balance.  If this pathway is hyper-activated, it leads to cell-cycle arrest.  On the other hand, 
carcinogenesis is also the result of aberrant activation of the Ras-Raf-MEK-ERK pathway 
(Cantwell-Dorris et al., 2011; Davies et al., 2002).  Mutations that are responsible for 
aberrant ERK signalling can present at different levels within the Ras-Raf-MEK-ERK 
pathway.  B-Raf mutation is one of common types of mutations that lead to aberrant ERK 
signalling (Garnett and Marais, 2004).  To avoid over activation of the Ras-Raf-MEK-ERK 
pathway and cell cycle arrest, ERK signalling should be maintained carefully (Kerkhoff and 
Rapp, 1998; Marshall, 1995; Sewing et al., 1997; Woods et al., 1997).  To do that some 
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multiple mutations are seen in the Ras-Raf-MEK-ERK pathway in cancer so that the cancer 
cells can still modulate ERK signalling despite aberrant pathway activity.   Therefore, some 
B-Raf mutations are seen along with Ras mutations in the same type of cancer, cooperating 
with each other to modulate ERK signalling (Davies et al., 2002; Garnett and Marais, 2004; 
Yuen et al., 2002b). However, B-Raf V600E mutation is not seen in the same type of cancer 
where Ras is mutated.  This may be because their combined stimulation will hyper-activate 
the ERK signalling pathway and will arrest the cell cycle (Davies et al., 2002; Garnett and 
Marais, 2004). 
 
Clinical impacts of B-Raf mutation 
Cancers arising through mutations in the Ras-Raf-MEK-ERK pathway are noted in 
approximately 30% of all cancers, where around 8% is due to B-Raf mutation (Davies et al., 
2002; Garnett and Marais, 2004).  The highest frequency of B-Raf mutations happens in 
melanoma (40-70%).  This mutation also commonly found in thyroid cancer (36-53%), 
colorectal cancer (5-22%) and ovarian serous cancer (~30%).   B-Raf mutation is also 
detected in others cancers such as gliomas, non-small cell lung carcinoma, hepatobiliary 
carcinoma and hairy cell leukaemia (Cantwell-Dorris et al., 2011; Davies et al., 2002; 
Dhomen and Marais, 2009; Garnett and Marais, 2004; Pakneshan et al., 2013; Zebisch and 
Troppmair, 2006).  In addition, B-Raf mutation has been related clinically to the histological 
subtypes and prognosis of patients in several cancers (Pakneshan et al., 2013; Smith et al., 
2011; Xing et al., 2013). 
Most of the B-Raf mutations are found in exon 11 or 15 of its catalytic kinase domain 
(Ikenoue et al., 2004; Zebisch and Troppmair, 2006).  So far, more than 65 B-Raf mutations 
have been discovered (Cantwell-Dorris et al., 2011; Davies et al., 2002; Roskoski, 2010).   
Among all the B-Raf mutations, V600E mutation is the most frequent type, making up more 
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than 90% of observed B-Raf mutations.  This mutation is a missense mutation in exon 15,  
occurring due to the substitution of the amino acid valine to glutamic acid at position 600 
(Davies et al., 2002). 
 
B-Raf wild-type and activation of MEK-ERK pathway 
Ras-Raf-MEK-ERK pathway is an important cellular functional pathway that works 
in response to extracellular stimuli like hormones, cytokines and various growth factors 
(Cantwell-Dorris et al., 2011; Garnett and Marais, 2004; Robinson and Cobb, 1997).  
Extracellular stimuli activate Ras (small G-protein) kinases through their respective receptor 
on the cell membrane (Fig. 2).  Activated Ras then recruits B-Raf protein from cytoplasm to 
the cell membrane.  With the help of adaptor proteins, Ras phosphorylates two important 
residues in B-Raf (residues T599 and S602) that are located in the activation segment of B-
Raf kinase domain (Garnett and Marais, 2004; Zhang and Guan, 2000). After being 
phosphorylated, B-Raf activates its downstream effectors MEK1 and MEK2 which 
afterwards phosphorylate ERK1 and ERK2.  Activated ERK1/2 then forwards the signals to 
its downstream effectors (both cytosolic and nuclear effectors) for cellular proliferation, 
differentiation, growth and survival (Cantwell-Dorris et al., 2011).  Experiments have shown 
that among the MEK kinase family, B-Raf only interacts with MEK1 and MEK2.  The reason 
behind this is that MEK1/2 contains a proline-rich segment in their carboxy-terminal which is 
essential for the interaction of B-Raf with MEK.  This proline-rich segment is absent among 
other MEK kinase family members and therefore these are unable to interact with B-Raf 
(Cantwell-Dorris et al., 2011; Catling et al., 1995; Robinson and Cobb, 1997).  
 
B-Raf mutation and activation of MEK-ERK pathway 
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The kinase domain of B-Raf adopts a bi-lobal structure which is separated by a 
catalytic cleft. These lobes are named as the small lobe and large lobe. The presence of 
aspartic acid in the N-region of B-Raf stabilizes its small lobe (Cantwell-Dorris et al., 2011; 
Garnett and Marais, 2004; Johnson et al., 1998).  However, the conserved aspartate, 
phenylalanine and glycine (DFG) motif of B-Raf undergoes flipped orientation in its inactive 
conformation (DFG-out).  As a result, the glycine rich loop and activation segment of B-Raf 
kinase domain are positioned close to each other which results in a hydrophobic interaction 
between these two regions.  This phenomenon makes the catalytic cleft inaccessible (Wan et 
al., 2004).  If, however, the hydrophobic interaction between the glycine rich loop and 
activation segment is disrupted due to phosphorylation in the activation segment, the DFG 
motif again flips to its active orientation (DFG-in) which makes the catalytic cleft accessible 
(Cantwell-Dorris et al., 2011; Wan et al., 2004).  
Most of the mutations in B-Raf happen in the glycine rich loop and activation 
segment.  More specifically, these mutations occur in the regions which are involved in the 
hydrophobic interaction between the glycine rich loop and activation segment, as well as in 
the residues which contribute to the stabilization of hydrophobic interaction between these 
two regions (Cantwell-Dorris et al., 2011; Garnett and Marais, 2004; Wan et al., 2004).  The 
consequence of mutations in these regions is destabilization of the hydrophobic interaction, 
locking of the protein in its active conformation and increases to the kinase activity of B-Raf 
(Garnett and Marais, 2004).  
The V600E mutation in B-Raf occurs near the DFG motif in the activation segment 
where valine is substituted with glutamic acid.  Valine has a hydrophobic medium sized side 
chain whereas glutamic acid is a negatively charged large side chain (Cantwell-Dorris et al., 
2011; Wan et al., 2004). This mutation destabilizes the hydrophobic interaction between the 
glycine rich loop and activation segment which results in the characteristic change of the 
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DFG motif to its active orientation and a 500 fold increase in its kinase activity (Cantwell-
Dorris et al., 2011; Wan et al., 2004).  This phenomenon makes B-Raf alone sufficient to 
send signals for cellular proliferation and survival to the cell.  Therefore, B-Raf itself can 
stimulate the MEK-ERK signalling pathway without any input from upstream effectors or 
external stimuli (Fig. 2).  This mutation’s constitutive activation of the MEK-ERK signalling 
pathway results uncontrolled cellular proliferation and survival activities (Cantwell-Dorris et 
al., 2011; Garnett and Marais, 2004; Wan et al., 2004).     
In B-Raf, there are a few mutations known (such as mutations in residues E586, 
D587, R682, A728, K439 and T440) that do not contribute to the destabilization of 
hydrophobic interaction between the glycine rich loop and activation segment (Garnett and 
Marais, 2004; Guan et al., 2000).  These mutations can, however, disrupt the inactive 
conformation of  B-Raf  by alternative mechanisms like disruption of intra-molecular 
interactions or affecting negative regulation of B-Raf by other pathways and subsequently 
result in activation of the MEK-ERK signalling pathway (Garnett and Marais, 2004).  
Some B-Raf mutations (including G466E, G466V and G596R) impair the kinase 
activity of B-Raf and as a result, B-Raf cannot activate MEK directly (Houben et al., 2004; 
Wan et al., 2004).  However, B-Raf is still able to keep activating MEK-ERK signalling in 
such cases.  This is achieved by B-Raf associating with wild-type C-Raf to form 
heterodimers.  The dimerization process is mediated by 14-3-3 regulatory proteins as this 
protein is able to bind both mutated B-Raf protein and the C-Raf protein.  C-Raf is then 
activated through transphosphorylation where mutant B-Raf activates the kinase domain of 
C-Raf (Garnett et al., 2005; Wan et al., 2004).  In this situation, activation of C-Raf does not 
require its N-region to be phosphorylated.  B-Raf phosphorylates the activation segment of C-
Raf directly or indirectly with the help of other kinase molecules where binding of B-Raf to 
C-Raf performs similar functions as phosphorylation of N-region residues in C-Raf (Dhomen 
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and Marais, 2007; Garnett et al., 2005; Wan et al., 2004).   Here, C-Raf activation happens in 
the cytosol which occurs in a Ras independent manner.  Afterwards, activated C-Raf 
phosphorylates the MEK kinase and MEK kinase then activates the ERK kinase (Dhomen 
and Marais, 2007; Garnett et al., 2005; Wan et al., 2004).  This phenomenon indicates that, 
irrespective of the effect on kinase activity, the main result of most B-Raf mutations is to 
increase activation of MEK-ERK signalling (Garnett and Marais, 2004). 
 
B-Raf mutation and activation of NF-κB signalling pathway 
B-Raf V600E mutation not only keeps activating the MEK-ERK signalling pathway, 
it also activates the NF-κB signalling pathway and Bcl-2 (Fig. 3).  The activation of NF-κB 
signalling pathways and Bcl-2 results in the inhibition of apoptosis which is a crucial step for 
carcinogenesis (Cox and Der, 2003; Dhomen and Marais, 2007; Garnett and Marais, 2004; 
Hingorani et al., 2003; Ikenoue et al., 2004; Ikenoue et al., 2003; Karasarides et al., 2004; 
Rapp et al., 2004).  B-Raf activates Bcl-2 and NF-κB by first binding with C-Raf.  As 
outlined above, both wild-type and mutated B-Raf can bind with C-Raf.  The binding of wild-
type B-Raf to C-Raf occurs in a Ras-dependent manner whereas binding of mutant B-Raf to 
C-Raf is a Ras-independent mechanism (Dhomen and Marais, 2007; Garnett et al., 2005; 
Wan et al., 2004).   It is worth noting that such binding is unidirectional and that C-Raf 
cannot activate B-Raf.  After binding with C-Raf, B-Raf activates C-Raf through the trans-
phosphorylation mechanism mentioned previously.  Phosphorylated C-Raf then activates 
both Bcl-2 and NF-κB which ultimately inhibit apoptosis (Chadee et al., 2006; Dhomen and 
Marais, 2007; Garnett et al., 2005; Rapp et al., 2004; Rushworth et al., 2006; Wan et al., 
2004; Weber et al., 2001).   
An activated NF-κB signalling pathway induces the expression of anti-apoptotic 
proteins like TRAF1, TRAF2, c-IAP1, c-IAP2, c-FLIP, ML-IAP, survivin as well as bcl-2-
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like proteins which play a dominant role in the inhibition of apoptosis (Amiri and Richmond, 
2005; Baldwin, 1996; Catz and Johnson, 2001; Deveraux et al., 1998; Hanahan and 
Weinberg, 2000; Micheau et al., 2001; Pacifico and Leonardi, 2010; Ravi et al., 2001; Wang 
et al., 1998).   Activation of the NF-κB signalling pathway not only inhibits apoptosis, but the 
activation also induces proliferation, angiogenesis, invasion and metastasis by regulating the 
expression of important cellular proteins like cyclin D1, CDK2, VEGF, ICAM-1, VCAM-1, 
ELAM-1 and MMPs.  These proteins are necessary for proliferation, angiogenesis, invasion 
and metastasis (Amiri and Richmond, 2005; Bash et al., 1997; Bond et al., 1998; Borghaei et 
al., 2004; Greten and Karin, 2004; Guttridge et al., 1999; Hanahan and Weinberg, 2000; Hinz 
et al., 1999; Iademarco et al., 1992; Kashani-Sabet et al., 2004; Pacifico and Leonardi, 2010; 
Palona et al., 2006; Rofstad and Halsor, 2000; van de Stolpe et al., 1994; Whelan et al., 
1991).  In addition, Bcl-2, survivin, cyclin D1 and VEGF were found to be important in the 
pathogenesis and as prognostic indicators for patients with cancer (Lam et al., 2008; Lam et 
al., 2000; Salajegheh et al., 2011; Yu et al., 2008a; Yu et al., 2008b; Yuen et al., 2002a). 
Activated NF-κB is also involved in the process of inflammation by regulating the 
expression and functions of different important pro-inflammatory cytokines and chemokines 
which ultimately leads to the development of cancer (Greten and Karin, 2004; Keates et al., 
1997; Mantovani et al., 2008; Pacifico and Leonardi, 2010; Pikarsky et al., 2004).  In 
addition, overexpression of P-glycoprotein encoded by multidrug resistance (MDR1) gene 
plays a dominant role in the development of resistance to conventional chemotherapy in 
cancer.  It has been found that expression of MDR1 gene is controlled by the NF-κB 
signalling pathway, making B-Raf signalling an important part of resistance to therapy as 
well as carcinogenesis (Amiri and Richmond, 2005; Deng et al., 2001; Kuo et al., 2002; Ng et 
al., 1998; Um et al., 2001; Wang et al., 1999; Zhou and Kuo, 1997).        
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B-Raf mutation in melanoma: 
Melanoma is a malignant tumour with the differentiation of the melanocytes, which 
are pigment cells usually seen in epidermis, meninges, inner ear and eye (Cantwell-Dorris et 
al., 2011; Davies et al., 2002; Dhomen and Marais, 2009).  In melanoma, B-Raf V600E 
mutation is often found along with p53 inactivating mutations (Daniotti et al., 2004).  This 
p53 deficiency helps melanoma nevi in overcoming the senescent state as well as becoming 
invasive (Michaloglou et al., 2005; Patton et al., 2005).  It has been discovered that B-Raf 
mutations are very rare in both chronic sun-induced damage melanomas as well as 
melanomas which occur in low sun exposure areas.  This phenomenon indicates that B-Raf 
mutations are more related to non-chronic sun-induced damage melanomas  which happen as 
a consequence of acute and high intensity ultraviolet  exposure (Cantwell-Dorris et al., 2011; 
Curtin et al., 2005; Dhomen and Marais, 2007).  Although B-Raf mutation is related to 
ultraviolet exposure, the relationship between them is not direct.  Melanin production in the 
presence of ultraviolet exposure causes accumulation of highly toxic oxidising agents which 
is markedly increased in case of acute and highly intensive ultraviolet exposure.  This 
accumulation of highly toxic oxidising agents cause increased DNA damage in melanocytes 
which contributes to occurrence of B-Raf mutation (d'Ischia et al., 1991; Dhomen and 
Marais, 2007; Nappi and Vass, 1996).     
B-Raf mutations are also related to variation in melanocortin-1 receptor (MC1R) and 
are more common in younger melanoma patients (Cantwell-Dorris et al., 2011; Curtin et al., 
2005; Landi et al., 2006; Urano et al., 1995).  Melanocortin-1 receptor is a G-protein coupled 
receptor which is found on melanocytes and is highly polymorphic in humans.  Wild-type 
MC1R is the fully active variant, but partially (r) or completely (R) impaired variants are also 
present on melanocytes.  It has been found that MC1R (r or R) variants are responsible for 
several distinct phenotypes in human (like red hair, fair skin as well as freckling) and people 
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bearing these alleles are more susceptible to ultraviolet radiation (Cantwell-Dorris et al., 
2011; Gerstenblith et al., 2007; Landi et al., 2006; Naysmith et al., 2004; Rouzaud et al., 
2005; Sturm et al., 2003; Valverde et al., 1996).  Indeed, B-Raf mutations are most frequent 
in MC1R (r or R) variant cells, whereas they are less common in wild-type MC1R melanoma 
(Dhomen and Marais, 2007; Landi et al., 2006).  In presence of ultraviolet radiation, alpha-
melanocyte stimulating hormone (α-MSH) up-regulates c-AMP production in conjugation 
with MC1R.  This event creates signalling for proliferation as well as melanogenesis which 
cascades through B-Raf to ERK.  This α-MSH signalling also helps in the reduction of 
ultraviolet -induced free radical formation as well as apoptosis (Abdel-Malek et al., 2008; 
Busca and Ballotti, 2000; Cantwell-Dorris et al., 2011).  Generally, wild type MC1R sends 
signals for eumelanin production over pheomelanin in presence of ultraviolet radiation.  
MC1R (r or R) variants are incapable of producing this signal due to partial or complete 
damage of their signalling ability, which results in pheomelanin accumulation.  This 
pheomelanin accumulation is carcinogenic as it up-regulates free radical formation in 
presence of UVR, which contributes to extensive DNA damage as well as B-Raf mutation 
(Cantwell-Dorris et al., 2011).  
Protein Kinase A (PKA) inhibits C-Raf in presence of high cAMP levels in 
melacocytes.  As a result, C-Raf cannot signal to MEK.  In this situation, only B-Raf is able 
to transmit signals from Ras to MEK (Dumaz et al., 2006).  The situation is almost the same 
in B-Raf mutated melanomas where signals are transmitted directly from mutated B-Raf to 
MEK and C-Raf is inhibited by PKA, as it is still responsive to alpha-melanocyte stimulating 
hormone (α-MSH).  On the other hand, in Ras mutated melanoma, mutated Ras uses only C-
Raf to transmit signal to MEK and this type of melanoma does not respond to α-MSH and 
subsequent inhibition of C-Raf by PKA (Dhomen and Marais, 2007; Dumaz et al., 2006).  
Although Ras activates B-Raf more efficiently than C-Raf, mutated Ras switches to C-Raf in 
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Ras mutated melanoma for signal transmission and mutations in both B-Raf and Ras are not 
seen in the same cells.  The reason behind this is that if B-Raf is used to transmit signal from 
mutated Ras to MEK that could hyper-activate the pathway, which will result cycle arrest and 
senescence (Dhomen and Marais, 2007; Gray-Schopfer et al., 2005; Marais et al., 1997).   
For proliferation and survival, melanocytes depend on integrin mediated cell adhesion 
to the extracellular matrix (ECM) (Howe et al., 2002).  Integrin regulates growth factor 
mediated activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) which triggers 
the upregulation of cyclin D1 as well as the downregulation of the cyclin dependent kinase 
inhibitor (cdk) p27kip1.  As a result, cell cycle progression through G1/S phase occurs.  
Experiments have shown that in case of failure of cellular adhesion to extracellular matrix 
(ECM), growth factor mediated activation of ERK1/2 are impaired (Assoian and Schwartz, 
2001; Cantwell-Dorris et al., 2011; Conner et al., 2003; Howe et al., 2002).  However, B-Raf 
V600E mutated melanoma cells do not depend on integrin mediated cell adhesion to the 
extracellular matrix (ECM) for proliferation and survival.  Rather, they bypass integrin and 
growth factor mediated activation of ERK1/2. They continue their proliferation in a way 
which is independent of adhesion to the ECM (Conner et al., 2003).  In addition, the 
constitutive activity of V600E mutated B-Raf in melanoma results in spontaneous ERK 
signalling which does not depend on upstream stimulation either from the ECM or growth 
factors (Bhatt et al., 2005; Cantwell-Dorris et al., 2011; Conner et al., 2003). 
 
B-Raf mutation in thyroid carcinoma: 
In endocrine malignancy, thyroid cancer is the most frequent type of cancer which is 
very common in women.  Among all thyroid cancers, the most frequent type of cancer is 
papillary thyroid carcinoma whose prevalence is almost 90% of thyroid cancers (Cantwell-
Page 13 of 35 
 
Dorris et al., 2011; Hundahl et al., 1998).  B-Raf mutation was first discovered in thyroid 
cancer in 2003 (Cohen et al., 2003; Namba et al., 2003).  B-Raf mutation is uniquely seen in 
papillary thyroid carcinoma and papillary thyroid caracinoma-derived undifferentiated 
thyroid carcinoma.  Prevalence of B-Raf mutation in papillary thyroid carcinoma  is 44% and 
in papillary thyroid carcinoma-derived undifferentiated  thyroid carcinoma is 24% (Xing, 
2005).  However, B-Raf mutation has not been reported in follicular thyroid carcinoma, 
medullary thyroid carcinoma, thyroid adenoma or nodular hyperplasia (Hundahl et al., 1998; 
Xing, 2005).  In addition, B-Raf mutation is found to be mutually exclusive with Ras 
mutation, RET/PTC rearrangement as well as other common genetic alterations in thyroid 
carcinoma (Xing, 2005).   
B-Raf mutation is most frequent in older age patients, conventional papillary thyroid 
carcinoma, carcinomas with extrathyroidal invasion as well as advanced stage carcinomas 
(Cantwell-Dorris et al., 2011; Ciampi and Nikiforov, 2007; Gu et al., 2009; Nikiforova et al., 
2003; Smith et al., 2011).  In addition, B-Raf mutation is associated with promotion of 
invasiveness in thyroid cancer (Palona et al., 2006).  This mutation is also associated with 
poorer clinicopathological outcome in papillary thyroid carcinoma  (Xing, 2005).  B-Raf 
mutation is also found to be associated with for clinical progression, recurrence and treatment 
failure in thyroid cancer patients.  Again, B-Raf mutation is also correlated with more 
aggressive and iodine-resistant phenotype in thyroid cancer.  Therefore, B-Raf mutation 
represents a prognostic marker of progression and aggressiveness of papillary thyroid 
carcinoma (Caronia et al., 2011; Riesco-Eizaguirre et al., 2006; Xing, 2007; Xing et al., 
2005).   
It has been reported in thyroid cancer that V600E mutant B-Raf is responsible for the 
suppression of several key genes like NIS, AIT-B, Tg and TPO which are involved in iodine 
metabolism (Durante et al., 2007; Liu et al., 2007; Tang and Lee, 2010).  In an experiment, 
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promoter methylation was found to be responsible for suppression of these iodine 
metabolizing genes in B-Raf mutated papillary thyroid carcinoma.  However, activities of 
these suppressed iodine metabolizing genes can be recovered through inhibition of MEK 
kinase, as the Ras-Raf-MEK-ERK pathway controls the activity of DNA methyltransferase 
(Cantwell-Dorris et al., 2011; Liu et al., 2007; Pruitt et al., 2005; Tang and Lee, 2010).  In 
addition, it has been found that B-Raf mutation is also associated with the silencing of the 
tumour suppressor gene SLC5A8 in classical papillary thyroid carcinoma (PTC) (Porra et al., 
2005).  
 
B-Raf mutation in colorectal carcinoma: 
Colorectal carcinoma is one of the most highly prevalent cancer types in the world 
which follows the Kinzler-Vogelstein model.  According to this model, step by step 
accumulation of p53 gene associated mutations and members of the β-catenin signalling 
pathway are responsible for the occurrence of adenocarcinoma (Boyle and Langman, 2000; 
Cantwell-Dorris et al., 2011; Fransen et al., 2004; Kinzler and Vogelstein, 1996).  Beside this 
most common route, another pathway to colorectal carcinoma development is the association 
of Ras-Raf-MEK-ERK pathway mutations and microsatellite instability (MSI) with the 
development of adenocarcinoma.  In this type of colorectal carcinoma, frequent mutations are 
found in both B-Raf and K-Ras proteins (Rajagopalan et al., 2002; Velho et al., 2008).  
However, mutations in the B-Raf and K-Ras proteins have been found to be mutually 
exclusive in colorectal cancer, as in other cancers (Fransen et al., 2004; Velho et al., 2008).  
B-Raf mutation is more associated with mismatch repair deficient tumour in colorectal cancer 
(Benhattar et al., 1993; Kikuchi et al., 2009; Rajagopalan et al., 2002).  It has been found that 
B-Raf mutation is 3-fold more frequent in mismatch repair deficient tumour when compared 
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to mismatch repair proficient tumour in colorectal cancer (Cantwell-Dorris et al., 2011; 
Rajagopalan et al., 2002). 
It has also been shown that there is a strong relationship between B-Raf mutation and 
CpG island methylation phenotype (CIMP) in colorectal cancer (Velho et al., 2008; 
Weisenberger et al., 2006).  In addition, CpG island methylation phenotype (CIMP) is related 
to high microsatellite instability (MSI-H) and shows methylation of the mismatch repair gene 
MLH1.  MLH1 contains a large CpG island in its promoter region and is involved in both 
mismatch repair as well as DNA damage signalling.  When methylation occurs near the 
transcriptional start site in the small proximal region (region C) of MLH1 gene, it results in 
the reduction of that gene’s expression (Cantwell-Dorris et al., 2011; Deng et al., 1999).  It 
has also been found that B-Raf mutations are prevalent in precursor lesions which denote that 
B-Raf mutations are a preliminary step in the pathway to these types of colorectal carcinomas 
(Cantwell-Dorris et al., 2011; Dong et al., 2005; Park et al., 2003; Yang et al., 2004). 
Mutant B-Raf CpG island methylation phenotype (CIMP) tumours often show serrated 
morphology which is believed to be a consequence of inhibition of apoptosis (Tateyama et 
al., 2002).  It has been shown that if B-Raf is over expressed, it can stop apoptosis through a 
post-mitochondrial regulation of apoptosis (Erhardt et al., 1999).  It has been also seen that 
mutant B-Raf is a potent inhibitor of apoptosis (Ikehara et al., 2005).  Mutant B-Raf is 
believed to create a microenvironment which is resistant to apoptosis and susceptible to 
promoter hypermethylation.  These phenomenon leads to extensive DNA damage as well as 
high microsatellite instability (MSI-H) which is responsible for the CpG island methylation 
phenotype (CIMP) colorectal carcinoma , explaining the close correlation between this 
phenotype and B-Raf mutation (Cantwell-Dorris et al., 2011; Minoo et al., 2007). In addition, 
B-Raf V600E mutation is also found to be associated with the development and maintenance 
of transformed and invasive phenotypes in colon epithelial cells (Minoo et al., 2007).  
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Conclusion 
Cancer is not a result of single genetic disorder; rather it happens as a consequence of 
multiple genetic alterations.  Some genetic disorders play dominant role in carcinogenesis 
and trigger other genetic alterations while predisposing to others; B-Raf mutation is one of 
them.  V600E mutant B-Raf not only plays a dominant role in uncontrolled cellular 
proliferation through spontaneous ERK signalling, but also controls apoptosis through 
constitutive NF-κB signalling.  Uncontrolled NF-κB signalling also triggers angiogenesis, 
invasion and metastatic processes.  All these events act to armour B-Raf mutated cancer cells 
against normal growth control mechanisms and make the further growth and progression of 
such cancer cells all the more likely. 
 
 
 
 
 
 
 
 
 
 
Page 17 of 35 
 
References 
Abdel-Malek, Z. A., et al., 2008. The melanocortin 1 receptor and the UV response of human 
melanocytes--a shift in paradigm. Photochem Photobiol. 84, 501-508. 
Amiri, K. I., Richmond, A., 2005. Role of nuclear factor-kappa B in melanoma. Cancer 
Metastasis Rev. 24, 301-313. 
Assoian, R. K., Schwartz, M. A., 2001. Coordinate signaling by integrins and receptor 
tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet 
Dev. 11, 48-53. 
Baldwin, A. S., Jr., 1996. The NF-kappa B and I kappa B proteins: new discoveries and 
insights. Annu Rev Immunol. 14, 649-683. 
Barnier, J. V., et al., 1995. The mouse B-raf gene encodes multiple protein isoforms with 
tissue-specific expression. J Biol Chem. 270, 23381-23389. 
Bash, J., et al., 1997. c-Rel arrests the proliferation of HeLa cells and affects critical 
regulators of the G1/S-phase transition. Mol Cell Biol. 17, 6526-6536. 
Benhattar, J., et al., 1993. Prognostic significance of K-ras mutations in colorectal carcinoma. 
Gastroenterology. 104, 1044-1048. 
Bhatt, K. V., et al., 2005. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in 
melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 24, 3459-3471. 
Bond, M., et al., 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and 
inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. 
FEBS Lett. 435, 29-34. 
Bonner, T. I., et al., 1985. Structure and biological activity of human homologs of the raf/mil 
oncogene. Mol Cell Biol. 5, 1400-1407. 
Borghaei, R. C., et al., 2004. NF-kappaB binds to a polymorphic repressor element in the 
MMP-3 promoter. Biochem Biophys Res Commun. 316, 182-188. 
Page 18 of 35 
 
Boyle, P., Langman, J. S., 2000. ABC Of Colorectal Cancer: Epidemiology. BMJ: British 
Medical Journal. 321, 805-808. 
Busca, R., Ballotti, R., 2000. Cyclic AMP a key messenger in the regulation of skin 
pigmentation. Pigment Cell Res. 13, 60-69. 
Cantwell-Dorris, E. R., et al., 2011. BRAFV600E: implications for carcinogenesis and 
molecular therapy. Mol Cancer Ther. 10, 385-394. 
Caronia, L. M., et al., 2011. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 17, 
7511-7517. 
Catling, A. D., et al., 1995. A proline-rich sequence unique to MEK1 and MEK2 is required 
for raf binding and regulates MEK function. Mol Cell Biol. 15, 5214-5225. 
Catz, S. D., Johnson, J. L., 2001. Transcriptional regulation of bcl-2 by nuclear factor kappa 
B and its significance in prostate cancer. Oncogene. 20, 7342-7351. 
Chadee, D. N., et al., 2006. Mixed-lineage kinase 3 regulates B-Raf through maintenance of 
the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc 
Natl Acad Sci U S A. 103, 4463-4468. 
Ciampi, R., Nikiforov, Y. E., 2007. RET/PTC rearrangements and BRAF mutations in 
thyroid tumorigenesis. Endocrinology. 148, 936-941. 
Cohen, Y., et al., 2003. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 
95, 625-627. 
Conner, S. R., et al., 2003. Adhesion-dependent activation of the ERK1/2 cascade is by-
passed in melanoma cells. J Biol Chem. 278, 34548-34554. 
Cox, A. D., Der, C. J., 2003. The dark side of Ras: regulation of apoptosis. Oncogene. 22, 
8999-9006. 
Curtin, J. A., et al., 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med. 
353, 2135-2147. 
Page 19 of 35 
 
d'Ischia, M., et al., 1991. Peroxidase as an alternative to tyrosinase in the oxidative 
polymerization of 5,6-dihydroxyindoles to melanin(s). Biochim Biophys Acta. 1073, 
423-430. 
Daniotti, M., et al., 2004. BRAF alterations are associated with complex mutational profiles 
in malignant melanoma. Oncogene. 23, 5968-5977. 
Davies, H., et al., 2002. Mutations of the BRAF gene in human cancer. Nature. 417, 949-954. 
Deng, G., et al., 1999. Methylation of CpG in a small region of the hMLH1 promoter 
invariably correlates with the absence of gene expression. Cancer Res. 59, 2029-2033. 
Deng, L., et al., 2001. 2-acetylaminofluorene up-regulates rat mdr1b expression through 
generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem. 
276, 413-420. 
Deveraux, Q. L., et al., 1998. IAPs block apoptotic events induced by caspase-8 and 
cytochrome c by direct inhibition of distinct caspases. EMBO J. 17, 2215-2223. 
Dhomen, N., Marais, R., 2007. New insight into BRAF mutations in cancer. Curr Opin Genet 
Dev. 17, 31-39. 
Dhomen, N., Marais, R., 2009. BRAF signaling and targeted therapies in melanoma. Hematol 
Oncol Clin North Am. 23, 529-545, ix. 
Dong, S. M., et al., 2005. Progressive methylation during the serrated neoplasia pathway of 
the colorectum. Mod Pathol. 18, 170-178. 
Dumaz, N., et al., 2006. In melanoma, RAS mutations are accompanied by switching 
signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 
9483-9491. 
Durante, C., et al., 2007. BRAF mutations in papillary thyroid carcinomas inhibit genes 
involved in iodine metabolism. J Clin Endocrinol Metab. 92, 2840-2843. 
Page 20 of 35 
 
Erhardt, P., et al., 1999. B-Raf inhibits programmed cell death downstream of cytochrome c 
release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 19, 
5308-5315. 
Fabian, J. R., et al., 1993. Critical tyrosine residues regulate the enzymatic and biological 
activity of Raf-1 kinase. Mol Cell Biol. 13, 7170-7179. 
Fransen, K., et al., 2004. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human 
colorectal adenocarcinomas. Carcinogenesis. 25, 527-533. 
Garnett, M. J., Marais, R., 2004. Guilty as charged: B-RAF is a human oncogene. Cancer 
Cell. 6, 313-319. 
Garnett, M. J., et al., 2005. Wild-type and mutant B-RAF activate C-RAF through distinct 
mechanisms involving heterodimerization. Mol Cell. 20, 963-969. 
Gerstenblith, M. R., et al., 2007. Comprehensive evaluation of allele frequency differences of 
MC1R variants across populations. Hum Mutat. 28, 495-505. 
Gray-Schopfer, V. C., et al., 2005. The role of B-RAF in melanoma. Cancer Metastasis Rev. 
24, 165-183. 
Greten, F. R., Karin, M., 2004. The IKK/NF-kappaB activation pathway-a target for 
prevention and treatment of cancer. Cancer Lett. 206, 193-199. 
Gu, L. Q., et al., 2009. BRAFV600E mutation and X-linked inhibitor of apoptosis expression 
in papillary thyroid carcinoma. Thyroid. 19, 347-354. 
Guan, K. L., et al., 2000. Negative regulation of the serine/threonine kinase B-Raf by Akt. J 
Biol Chem. 275, 27354-27359. 
Guttridge, D. C., et al., 1999. NF-kappaB controls cell growth and differentiation through 
transcriptional regulation of cyclin D1. Mol Cell Biol. 19, 5785-5799. 
Hanahan, D., Weinberg, R. A., 2000. The hallmarks of cancer. Cell. 100, 57-70. 
Page 21 of 35 
 
Hingorani, S. R., et al., 2003. Suppression of BRAF(V599E) in human melanoma abrogates 
transformation. Cancer Res. 63, 5198-5202. 
Hinz, M., et al., 1999. NF-kappaB function in growth control: regulation of cyclin D1 
expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19, 2690-2698. 
Houben, R., et al., 2004. Constitutive activation of the Ras-Raf signaling pathway in 
metastatic melanoma is associated with poor prognosis. J Carcinog. 3, 6. 
Howe, A. K., et al., 2002. Anchorage-dependent ERK signaling--mechanisms and 
consequences. Curr Opin Genet Dev. 12, 30-35. 
Huebner, K., et al., 1986. Actively transcribed genes in the raf oncogene group, located on 
the X chromosome in mouse and human. Proc Natl Acad Sci U S A. 83, 3934-3938. 
Hundahl, S. A., et al., 1998. A National Cancer Data Base report on 53,856 cases of thyroid 
carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 83, 2638-2648. 
Iademarco, M. F., et al., 1992. Characterization of the promoter for vascular cell adhesion 
molecule-1 (VCAM-1). J Biol Chem. 267, 16323-16329. 
Ikawa, S., et al., 1988. B-raf, a new member of the raf family, is activated by DNA 
rearrangement. Mol Cell Biol. 8, 2651-2654. 
Ikehara, N., et al., 2005. BRAF mutation associated with dysregulation of apoptosis in human 
colorectal neoplasms. Int J Cancer. 115, 943-950. 
Ikenoue, T., et al., 2004. Different effects of point mutations within the B-Raf glycine-rich 
loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated 
kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway 
and cellular transformation. Cancer Res. 64, 3428-3435. 
Ikenoue, T., et al., 2003. Functional analysis of mutations within the kinase activation 
segment of B-Raf in human colorectal tumors. Cancer Res. 63, 8132-8137. 
Page 22 of 35 
 
Johnson, L. N., et al., 1998. The Eleventh Datta Lecture. The structural basis for substrate 
recognition and control by protein kinases. FEBS Lett. 430, 1-11. 
Karasarides, M., et al., 2004. B-RAF is a therapeutic target in melanoma. Oncogene. 23, 
6292-6298. 
Kashani-Sabet, M., et al., 2004. NF-kappa B in the vascular progression of melanoma. J Clin 
Oncol. 22, 617-623. 
Keates, S., et al., 1997. Helicobacter pylori infection activates NF-kappa B in gastric 
epithelial cells. Gastroenterology. 113, 1099-1109. 
Kerkhoff, E., Rapp, U. R., 1998. High-intensity Raf signals convert mitotic cell cycling into 
cellular growth. Cancer Res. 58, 1636-1640. 
Kikuchi, H., et al., 2009. Oncogenic KRAS and BRAF differentially regulate hypoxia-
inducible factor-1alpha and -2alpha in colon cancer. Cancer Res. 69, 8499-8506. 
Kinzler, K. W., Vogelstein, B., 1996. Lessons from hereditary colorectal cancer. Cell. 87, 
159-170. 
Kuo, M. T., et al., 2002. Induction of human MDR1 gene expression by 2-
acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase 
pathway that activate NF-kappaB signaling. Oncogene. 21, 1945-1954. 
Lam, A. K., et al., 2008. Quantitative analysis of survivin in colorectal adenocarcinoma: 
increased expression and correlation with telomerase activity. Hum Pathol. 39, 1229-
1233. 
Lam, K. Y., et al., 2000. Cyclin D1 expression in oral squamous cell carcinomas: 
clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med. 
29, 167-172. 
Landi, M. T., et al., 2006. MC1R germline variants confer risk for BRAF-mutant melanoma. 
Science. 313, 521-522. 
Page 23 of 35 
 
Liu, D., et al., 2007. Suppression of BRAF/MEK/MAP kinase pathway restores expression of 
iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin 
Cancer Res. 13, 1341-1349. 
Mantovani, A., et al., 2008. Cancer-related inflammation. Nature. 454, 436-444. 
Marais, R., et al., 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine 
phosphorylation. EMBO J. 14, 3136-3145. 
Marais, R., et al., 1997. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras 
and tyrosine kinases. J Biol Chem. 272, 4378-4383. 
Marshall, C. J., 1995. Specificity of receptor tyrosine kinase signaling: transient versus 
sustained extracellular signal-regulated kinase activation. Cell. 80, 179-185. 
Mason, C. S., et al., 1999. Serine and tyrosine phosphorylations cooperate in Raf-1, but not 
B-Raf activation. EMBO J. 18, 2137-2148. 
Michaloglou, C., et al., 2005. BRAFE600-associated senescence-like cell cycle arrest of 
human naevi. Nature. 436, 720-724. 
Micheau, O., et al., 2001. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 
21, 5299-5305. 
Minoo, P., et al., 2007. Role of BRAF-V600E in the serrated pathway of colorectal 
tumourigenesis. J Pathol. 212, 124-133. 
Moelling, K., et al., 1984. Serine- and threonine-specific protein kinase activities of purified 
gag-mil and gag-raf proteins. Nature. 312, 558-561. 
Morrison, D. K., Cutler, R. E., 1997. The complexity of Raf-1 regulation. Curr Opin Cell 
Biol. 9, 174-179. 
Morrison, D. K., et al., 1993. Identification of the major phosphorylation sites of the Raf-1 
kinase. J Biol Chem. 268, 17309-17316. 
Page 24 of 35 
 
Namba, H., et al., 2003. Clinical implication of hot spot BRAF mutation, V599E, in papillary 
thyroid cancers. J Clin Endocrinol Metab. 88, 4393-4397. 
Nappi, A. J., Vass, E., 1996. Hydrogen peroxide generation associated with the oxidations of 
the eumelanin precursors 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic 
acid. Melanoma Res. 6, 341-349. 
Naysmith, L., et al., 2004. Quantitative measures of the effect of the melanocortin 1 receptor 
on human pigmentary status. J Invest Dermatol. 122, 423-428. 
Ng, I. O., et al., 1998. Expression of P-glycoprotein, a multidrug-resistance gene product, is 
induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer. 83, 
851-857. 
Nikiforova, M. N., et al., 2003. BRAF mutations in thyroid tumors are restricted to papillary 
carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary 
carcinomas. J Clin Endocrinol Metab. 88, 5399-5404. 
Pacifico, F., Leonardi, A., 2010. Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol. 
321, 29-35. 
Pakneshan, S., et al., 2013. Clinicopathological relevance of BRAF mutations in human 
cancer. Pathology. 45, 346-356. 
Palona, I., et al., 2006. BRAFV600E promotes invasiveness of thyroid cancer cells through 
nuclear factor kappaB activation. Endocrinology. 147, 5699-5707. 
Park, S. J., et al., 2003. Frequent CpG island methylation in serrated adenomas of the 
colorectum. Am J Pathol. 162, 815-822. 
Patton, E. E., et al., 2005. BRAF mutations are sufficient to promote nevi formation and 
cooperate with p53 in the genesis of melanoma. Curr Biol. 15, 249-254. 
Pikarsky, E., et al., 2004. NF-kappaB functions as a tumour promoter in inflammation-
associated cancer. Nature. 431, 461-466. 
Page 25 of 35 
 
Porra, V., et al., 2005. Silencing of the tumor suppressor gene SLC5A8 is associated with 
BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 
90, 3028-3035. 
Pruitt, K., et al., 2005. Ras-mediated loss of the pro-apoptotic response protein Par-4 is 
mediated by DNA hypermethylation through Raf-independent and Raf-dependent 
signaling cascades in epithelial cells. J Biol Chem. 280, 23363-23370. 
Rajagopalan, H., et al., 2002. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair 
status. Nature. 418, 934. 
Rapp, U. R., et al., 1983. Structure and biological activity of v-raf, a unique oncogene 
transduced by a retrovirus. Proc Natl Acad Sci U S A. 80, 4218-4222. 
Rapp, U. R., et al., 2004. Bcl-2 proteins: master switches at the intersection of death signaling 
and the survival control by Raf kinases. Biochim Biophys Acta. 1644, 149-158. 
Ravi, R., et al., 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced 
apoptosis by NF-kappaB. Nat Cell Biol. 3, 409-416. 
Riesco-Eizaguirre, G., et al., 2006. The oncogene BRAF V600E is associated with a high risk 
of recurrence and less differentiated papillary thyroid carcinoma due to the 
impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 13, 257-269. 
Robinson, M. J., Cobb, M. H., 1997. Mitogen-activated protein kinase pathways. Curr Opin 
Cell Biol. 9, 180-186. 
Rofstad, E. K., Halsor, E. F., 2000. Vascular endothelial growth factor, interleukin 8, platelet-
derived endothelial cell growth factor, and basic fibroblast growth factor promote 
angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60, 4932-
4938. 
Roskoski, J. R., 2010. RAF protein-serine/threonine kinases: structure and regulation. 
Biochemical and biophysical research communications. 399, 313-317. 
Page 26 of 35 
 
Rouzaud, F., et al., 2005. MC1R and the response of melanocytes to ultraviolet radiation. 
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS 
OF MUTAGENESIS. 571, 133-152. 
Rushworth, L. K., et al., 2006. Regulation and role of Raf-1/B-Raf heterodimerization. Mol 
Cell Biol. 26, 2262-2272. 
Salajegheh, A., et al., 2011. Single nucleotide polymorphisms and mRNA expression of 
VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. 
Eur J Surg Oncol. 37, 93-99. 
Sewing, A., et al., 1997. High-intensity Raf signal causes cell cycle arrest mediated by 
p21Cip1. Mol Cell Biol. 17, 5588-5597. 
Smith, R. A., et al., 2011. Correlation between BRAF mutation and the clinicopathological 
parameters in papillary thyroid carcinoma with particular reference to follicular 
variant. Hum Pathol. 42, 500-506. 
Storm, S. M., et al., 1990. Expression of raf family proto-oncogenes in normal mouse tissues. 
Oncogene. 5, 345-351. 
Sturm, R. A., et al., 2003. The role of melanocortin-1 receptor polymorphism in skin cancer 
risk phenotypes. Pigment Cell Res. 16, 266-272. 
Tang, K. T., Lee, C. H., 2010. BRAF mutation in papillary thyroid carcinoma: pathogenic 
role and clinical implications. J Chin Med Assoc. 73, 113-128. 
Tateyama, H., et al., 2002. Apoptosis index and apoptosis-related antigen expression in 
serrated adenoma of the colorectum: the saw-toothed structure may be related to 
inhibition of apoptosis. Am J Surg Pathol. 26, 249-256. 
Um, J. H., et al., 2001. Increased and correlated nuclear factor-kappa B and Ku autoantigen 
activities are associated with development of multidrug resistance. Oncogene. 20, 
6048-6056. 
Page 27 of 35 
 
Urano, Y., et al., 1995. Frequent p53 accumulation in the chronically sun-exposed epidermis 
and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell 
carcinoma. J Invest Dermatol. 104, 928-932. 
Valverde, P., et al., 1996. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is 
associated with melanoma. Hum Mol Genet. 5, 1663-1666. 
van de Stolpe, A., et al., 1994. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis 
factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by 
dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 
promoter. J Biol Chem. 269, 6185-6192. 
Velho, S., et al., 2008. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps 
and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC 
Cancer. 8, 255. 
Wan, P. T., et al., 2004. Mechanism of activation of the RAF-ERK signaling pathway by 
oncogenic mutations of B-RAF. Cell. 116, 855-867. 
Wang, C. Y., et al., 1999. Control of inducible chemoresistance: enhanced anti-tumor therapy 
through increased apoptosis by inhibition of NF-kappaB. Nat Med. 5, 412-417. 
Wang, C. Y., et al., 1998. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-
IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281, 1680-1683. 
Weber, C. K., et al., 2001. Active Ras induces heterodimerization of cRaf and BRaf. Cancer 
Res. 61, 3595-3598. 
Weisenberger, D. J., et al., 2006. CpG island methylator phenotype underlies sporadic 
microsatellite instability and is tightly associated with BRAF mutation in colorectal 
cancer. Nat Genet. 38, 787-793. 
Wellbrock, C., Karasarides, M., 2004. The RAF proteins take centre stage. Nature Reviews 
Molecular Cell Biology. 5, 875-885. 
Page 28 of 35 
 
Whelan, J., et al., 1991. An NF kappa B-like factor is essential but not sufficient for cytokine 
induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. 
Nucleic Acids Res. 19, 2645-2653. 
Wittinghofer, A., Nassar, N., 1996. How Ras-related proteins talk to their effectors. Trends 
Biochem Sci. 21, 488-491. 
Woods, D., et al., 1997. Raf-induced proliferation or cell cycle arrest is determined by the 
level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 17, 5598-5611. 
Xing, M., 2005. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12, 245-262. 
Xing, M., 2007. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular 
bases, and clinical implications. Endocr Rev. 28, 742-762. 
Xing, M., et al., 2013. Association between BRAF V600E mutation and mortality in patients 
with papillary thyroid cancer. JAMA. 309, 1493-1501. 
Xing, M., et al., 2005. BRAF mutation predicts a poorer clinical prognosis for papillary 
thyroid cancer. J Clin Endocrinol Metab. 90, 6373-6379. 
Yang, S., et al., 2004. BRAF and KRAS Mutations in hyperplastic polyps and serrated 
adenomas of the colorectum: relationship to histology and CpG island methylation 
status. Am J Surg Pathol. 28, 1452-1459. 
Yao, B., et al., 1995. Phosphorylation of Raf by ceramide-activated protein kinase. Nature. 
378, 307-310. 
Yu, X. M., et al., 2008a. The potential clinical relevance of serum vascular endothelial 
growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. 
Surgery. 144, 934-940; discussion 940-931. 
Yu, X. M., et al., 2008b. Serum vascular endothelial growth factor C correlates with lymph 
node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann 
Surg. 247, 483-489. 
Page 29 of 35 
 
Yuen, A. P., et al., 2002a. Clinicopathologic significance of bcl-2 expression in the surgical 
treatment of oral tongue carcinoma. Eur J Surg Oncol. 28, 667-672. 
Yuen, S. T., et al., 2002b. Similarity of the phenotypic patterns associated with BRAF and 
KRAS mutations in colorectal neoplasia. Cancer Res. 62, 6451-6455. 
Zebisch, A., Troppmair, J., 2006. Back to the roots: the remarkable RAF oncogene story. 
Cellular and Molecular Life Sciences. 63, 1314-1330. 
Zhang, B. H., Guan, K. L., 2000. Activation of B-Raf kinase requires phosphorylation of the 
conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439. 
Zhou, G., Kuo, M. T., 1997. NF-kappaB-mediated induction of mdr1b expression by insulin 
in rat hepatoma cells. J Biol Chem. 272, 15174-15183. 
Zimmermann, S., Moelling, K., 1999. Phosphorylation and regulation of Raf by Akt (protein 
kinase B). Science. 286, 1741-1744. 
 
 
 
 
 
 
 
 
 
 
Page 30 of 35 
 
Figure Legends 
 
Figure 1:  Linear structure of Raf proteins.  Three conserved regions of A-Raf, B-Raf and C-
Raf proteins are: CR1, CR2 and CR3.  Other important regions in Raf proteins are also 
indicated.  The most important residues in each Raf proteins are numbered.  In B-Raf, S446 is 
a constitutively phosphorylated residue and aspartic acid replaces the tyrosine residue at 
D449.  Regulatory protein 14-3-3 binding sites in each Raf proteins are shown.  RBD: Ras 
Binding Domain, CRD: Cysteine Rich Domain, N-region: Negatively Charged Region.     
 
Figure 2:  Activation of ERK signalling pathway through wild-type B-Raf and V600E 
Mutated B-Raf.  In cells where B-Raf is wild-type, proliferation and survival signals transfer 
through a cascade which starts from receptor tyrosine kinases (RTKs).  This proliferation and 
survival signal then passes through Ras, B-Raf, MEK, ERK and finally activates different 
downstream effector transcription factors responsible for proliferation and survival.  
However, when B-Raf is mutated (especially V600E mutated), the proliferation and survival 
signal is truncated as V600E mutated B-Raf itself is able to send spontaneous proliferation 
and survival signals without stimulation from the upstream signalling molecule Ras.  As a 
result, B-Raf V600E mutated cells show uncontrolled proliferation and survival.  Pathway 
elements made redundant by B-Raf mutation are shown with dotted arrows, mutant B-Raf 
activated pathway elements are indicated with solid arrows and mutant B-Raf protein is 
indicated with a solid star.       
 
Figure 3:  Activation of NF-κB signalling pathway through V600E mutated B-Raf.  In cell, 
V600E mutated B-Raf forms a dimer with C-Raf and activates C-Raf through 
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transphosphorylation.  Phosphorylated C-Raf is then able to activate MEK, Bcl-2 as well as 
NF-κB.  Activation of Bcl-2 and NF-κB trigger anti-apoptotic activities in addition to MEK 
activated proliferation.  Moreover, activation of NF-κB also triggers proliferation, 
angiogenesis, invasion and metastasis.  Pathway elements made redundant by B-Raf mutation 
are shown with dotted arrows, mutant B-Raf activated pathway elements are indicated with 
solid arrows and mutant B-Raf protein is indicated with a solid star.   
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